Emerging Drugs for Residual CV Risk in Statin-Treated Adults Emerging Drugs for Residual CV Risk in Statin-Treated Adults

Learn about the many novel therapeutics recently approved or under development which target LDL-C and/or triglycerides via different mechanisms than do statins.American Journal of Cardiovascular Drugs
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news